Imunon, Inc. Files 8-K for Operations and Financials
Ticker: IMNN · Form: 8-K · Filed: May 13, 2024 · CIK: 749647
| Field | Detail |
|---|---|
| Company | Imunon, INC. (IMNN) |
| Form Type | 8-K |
| Filed Date | May 13, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: IMNN
TL;DR
IMNN filed an 8-K for financial updates, check the filing for details.
AI Summary
Imunon, Inc. filed an 8-K on May 13, 2024, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing does not contain specific financial figures or operational updates beyond the general reporting categories.
Why It Matters
This 8-K filing indicates Imunon, Inc. is providing standard updates on its financial condition and operations to the SEC. Investors should review the full filing for specific details.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for reporting financial condition and operations, without immediate news of significant events.
Key Players & Entities
- Imunon, Inc. (company) — Registrant
- May 13, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-15911 (identifier) — Commission File Number
- 52-1256615 (identifier) — IRS Employer Identification No.
- 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311 (address) — Principal executive office address
FAQ
What is the primary purpose of this 8-K filing by Imunon, Inc.?
The primary purpose of this 8-K filing is to report on Imunon, Inc.'s results of operations and financial condition, and to file financial statements and exhibits.
On what date was this 8-K filing reported as of?
The earliest event reported in this 8-K filing was as of May 13, 2024.
In which U.S. state is Imunon, Inc. incorporated?
Imunon, Inc. is incorporated in Delaware.
What is Imunon, Inc.'s principal executive office address?
Imunon, Inc.'s principal executive office is located at 997 Lenox Drive, Suite 100, Lawrenceville, NJ 08648-2311.
Does this filing provide specific financial figures or operational updates?
This filing indicates it is for reporting results of operations and financial condition, and filing financial statements and exhibits, but does not provide specific figures or detailed operational updates within the provided text.
Filing Stats: 634 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2024-05-13 08:05:36
Key Financial Figures
- $0.01 — ch registered Common stock, par value $0.01 per share IMNN Nasdaq Capital Marke
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex99-1.htm (EX-99.1) — 91KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001493152-24-018791.txt ( ) — 322KB
- imnn-20240513.xsd (EX-101.SCH) — 3KB
- imnn-20240513_lab.xml (EX-101.LAB) — 33KB
- imnn-20240513_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On May 13, 2024, Imunon, Inc. issued a press release reporting its financial results for the quarter ended March 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. On May 6, 2024, Imunon, Inc. announced it would hold a conference call on May 13, 2024 to discuss its financial results for the quarter ended March 31, 2024 and provide a business update. The conference call will also be broadcast live on the internet at http://www.imunon.com . The information in this report, including the exhibit hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. Such information shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by Imunon, Inc., whether made before or after the date hereof, regardless of any general incorporation language in such filing. The press release contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Please refer to the cautionary note in the press release regarding these
forward-looking statements
forward-looking statements. Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release titled "Imunon Reports First Quarter 2024 Financial Results and Provides Business Update" issued by Imunon, Inc. on May 13, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IMUNON INC. Dated: May 13, 2024 By: /s/ Jeffrey W. Church Jeffrey W. Church Executive Vice President and Chief Financial Officer